Medpace Holdings Inc
Company Profile
Business description
Medpace is a late-stage contract research organization that provides full-service drug-development and clinical trial services to small and midsize biotechnology, pharmaceutical, and medical device firms. It also offers ancillary services, including bioanalytical laboratory services and imaging capabilities. The company was founded over 30 years ago and has more than 5,400 employees across 40 countries. Medpace is headquartered in Cincinnati, Ohio, and its operations are primarily based in the US, with additional presence in Europe, Asia, South America, Africa, and Australia. Cinven, a global private equity firm, acquired Medpace for $915 million in 2014 and exited its investment in 2018.
Contact
5375 Medpace Way
CincinnatiOH45227
USAT: +1 513 579-9911
Sector
Healthcare
Stock type
Defensive
Industry
Diagnostics & Research
Fiscal Year End
31 December 2025
Employees
6,000
Stocks News & Analysis
stocks
Has the most hated company on the ASX 200 bounced back?
stocks
Amazon earnings: Good results, with AWS still a winner; fear on profitability guidance is overblown
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,903.50 | 95.50 | -1.06% |
| CAC 40 | 7,546.16 | 225.81 | -2.91% |
| DAX 40 | 23,425.97 | 639.50 | -2.66% |
| Dow JONES (US) | 43,588.58 | 542.40 | -1.23% |
| FTSE 100 | 9,068.58 | 64.23 | -0.70% |
| HKSE | 24,608.64 | 164.69 | -0.66% |
| NASDAQ | 20,650.13 | 472.31 | -2.24% |
| Nikkei 225 | 40,192.24 | 877.58 | -2.14% |
| NZX 50 Index | 12,724.80 | 98.94 | -0.77% |
| S&P 500 | 6,238.01 | 101.38 | -1.60% |
| S&P/ASX 200 | 8,646.80 | 96.00 | -1.10% |
| SSE Composite Index | 3,567.02 | 7.07 | 0.20% |